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Abstract: Gemcitabine is an anticancer agent rapidly deaminated to the inactive metabolite
2′,2′-difluorodeoxyuridine. Its stability as well as bioavailability can be increased by making
prodrugs. A series of lipophilic prodrugs of gemcitabine were synthesized by linking the 4-amino
group with valeroyl, lauroyl, and stearoyl linear acyl derivatives. We studied, by the differential
scanning calorimetry technique, and compared the interaction of pure gemcitabine and its
prodrugs with dimyristoylphosphatidylcholine and distearoylphosphatidylcholine vesicles with
the aim of demonstrating if the gemcitabine prodrug is more able than the pure gemcitabine to
interact with lipid vesicles employed both as model biomembranes and as carriers in the transport
of antitumor drugs. These studies, carried out by static and kinetic calorimetric measurements,
give evidence that the increase of the prodrug’s lipophilic character improves the interaction
with lipid bilayers, favoring the absorption through the lipid barriers and allowing the liposomes
to work (when the prodrug is inserted inside the vesicles) as a lipophilic carrier which is able to
deliver the drug near the cell surface. The use of different prodrugs modified in their lipophilic
character, of different kinds of vesicles (multilamellar and unilamellar), and of different kinds of
vesicles forming phospholipids permitted us to determine the better equilibrium between in-
vesicle solubility and through-vesicle diffusion of the drug, important in the preformulative studies
of antitumor carriers based on phospholipid formulations. Such studies suggest that the prodrug
lipophilic tail should modulate the transport and the release of gemcitabine inside the cellular
compartments, and the efficiency of the liposomal system is related to the length of the prodrug’s
acyl chain which has to match the phospholipid acyl chain allowing or retarding the migration
through the lipid release device.
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Introduction
Gemcitabine (2′,2′-difluorodeoxycytidine) is a pyrimidine
antimetabolite structurally and pharmacologically similar to
cytarabine (Ara-C), specifically developed to extend the
activity of Ara-C to nonhematological malignancies. When
used in monotherapy, gemcitabine is indicated for pancreatic
cancer and non-small cell lung cancer,1 but it has also
demonstrated activity against many solid tumors.2 Gemcit-
abine is rapidly and extensively deaminated by cytidine
deaminase in blood, liver, kidney, and other tissues to the
inactive metabolite 2′,2′-difluorodeoxyuridine and excreted
in the urine, showing a very short plasma half-life (8-17
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min).1 Many different approaches have been tried to improve
gemcitabine metabolic stability and, consequently, its “in
vivo” cytotoxic activity. Eli Lilly patented the synthesis of
saturated and monounsaturated C18 and C20 long-chain
4-(N)-acyl-derivatives and 5′-esters of gemcitabine. It has
been shown that liposomes provide protection against rapid
metabolic inactivation of drugs.3 Nevertheless, low-molec-
ular-weight water-soluble molecules, such as 5-fluorouridine
or Ara-C, a drug strictly related to gemcitabine, rapidly
diffuse through the liposome bilayers4,5 thus limiting the shelf
life and clinical utility of these liposomes. To overcome this
problem, a large number of lipophilic prodrugs of 5-fluo-
rouridine or Ara-C have been synthesized5-7 and encapsu-
lated in liposomes, with high efficiency. The in vivo
antitumor activity of these liposomal prodrugs against a
variety of tumors is generally superior to that of the pure
drug.8,9
Recently, the synthesis and encapsulation in liposomes of
a series of gemcitabine 4-(N)-acyl derivatives prodrugs was
reported.10 The presence of an acyl moiety in the prodrugs
exerts a 2-fold action: (a) to increase the physical chemistry
properties so as to make it more lipophilic and consequently
more ready to be inserted in the lipid vesicles; (b) to
chemically protect the amidic group in the N-4 position of
cytosine that is rapidly metabolized in plasma.
The gemcitabine (Gem) and three of its prodrugs, 4-(N)-
valeroyl-gemcitabine (Gem-C5), 4-(N)-lauroyl-gemcitabine
(Gem-C12), and 4-(N)-stearoyl-gemcitabine (Gem-C18) (Fig-
ure 1), were here considered with the aim of evaluating the
effect of the length of the acyl chain on the ability to interact
with the biomembrane model in an aqueous environment.
Such interactions can be studied by differential scanning
calorimetry (DSC), a nonperturbative technique largely
employed to detect the effects exerted by biomolecules on
the lipid bilayers of a cell-like membrane in the processes
of entrapment and release inside lipid vesicles.11,12
Lipid membranes (multilamellar and unilamellar vesicles,
MLV and LUV, are usually employed as synthetic simplified
model membranes) undergo a sharp phase transition from
an ordered gel-like structure to a disordered fluidlike
structure. The differential scanning calorimetry technique can
detect such a phase change. The presence of foreign
substances dissolved in the lipid bilayer strongly affects the
thermodynamic properties of the phase transition, sometimes
causing variations in the phase transition temperature (Tm).
The amplitude of the effect can depend on the amount of
chemicals dissolved in the lipid structure.13-18
(1) Eli Lilly, Co. Summary of product characteristics: gemcitabine,
1997 UK prescribing information, Eli Lilly.
(2) Sandler, A.; Ettinger, D. S. Gemcitabine: single-agent and
combination therapy in non-small cell lung cancer. Oncologist
1999, 4, 241-251.
(3) Cattel, L.; Ceruti, M.; Dosio, F. From conventional to stealth
liposomes: a new frontier in cancer chemotherapy. Tumori 2003,
89, 237-249.
(4) Patel, K.; Baldeschwieler, J. D. Treatment of intravenously
implanted Lewis lung carcinoma with liposome-encapsulated
cytosine arabinoside and non-specific immunotherapy. Int. J.
Cancer 1984, 34, 415-420.
(5) Crosasso, P.; Brusa, P.; Dosio, F.; Arpicco, S.; Pacchioni, D.;
Shuber, F.; Cattel, L. Antitumoral activity of liposomes and
immunoliposomes containing 5-fluorouridine prodrugs. J. Pharm.
Sci. 1997, 86, 832-839.
(6) Rubas, W.; Supersaxo, A.; Weder, H. G.; Hartmann, H. R.;
Hengartner, H.; Scott, H.; Schwendener, R. Treatment of murine
L-1210 lymphoid leukemia and melanoma B16 with lipophilic
cytosine arabinoside prodrugs incorporated into unilamellar lip-
osomes. Int. J. Cancer 1986, 37, 149-154.
(7) Tokunaga, Y.; Iwasa, T.; Fujisaki, J.; Sawai, S.; Kagayama, A.
antitumor activity of newly synthetised lipophilic 1-beta-D-
arabinofuranocytosine prodrugs bearing liposomes. Chem. Pharm.
Bull. 1988, 36, 3574-3583.
(8) Moog, R.; Burger, A. M.; Brandl, M.; Schqler, J.; Shubert, R.;
Unger, C.; Fiebig, H. H.; Massing, U. Change in pharmacokinetic
and pharmacodynamic behavior of gemcitabine in human tumor
xenografts upon entrapment in vesicular phospholipid gels. Cancer
Chemother. Pharmacol. 2002, 49, 356-366.
(9) Zhang, J.-A.; Ahmad, I. Liposomal gemcitabine compositions for
better drug delivery. WO 2004017944, March 4, 2004.
(10) Immordino, M. L.; Brusa, P.; Rocco, F.; Arpicco, S.; Ceruti, M.;
Cattel, L. Preparation, characterization, cytotoxicity and pharma-
cokinetics of liposomes containing lipophilic gemcitabine prodrus.
J. Controlled Release 2004, 100, 331-346.
(11) Castelli, F.; Messina, C.; Sarpietro, M. G.; Pignatello, R.; Puglisi,
G. Flurbiprofen release from eudragit rs and rl aqueous nanosus-
pensions: a kinetic study by DSC and dialysis experiments. AAPS
PharmSciTech 2002, 3 article 9, 1-13.
(12) Castelli, F.; Raudino, A.; Fresta, M. A mechanistic study of the
permeation kinetics through biomembrane models: Gemcitabine-
phospholipid bilayer interaction. J. Colloid Interface Sci. 2005,
285, 110-117.
(13) Lohner, K. Effects of small organic molecules on phospholipid
through cell dissolution apparatus. Chem. Phys. Lipids 1991, 57,
341-362.
(14) Silvius, J. R. Thermotropic properties of phospholipid analogues.
Chem. Phys. Lipids 1991, 57, 241-252.
(15) Bach, D. Calorimetric studies of model and natural biomembranes.
In Biomembrane Structure and Function; Chapman, D., Ed.;
MacMillan Press: London, 1994; pp 1-41.
Figure 1. Gemcitabine and 4-(N)-acyl-gemcitabine prodrug
structure.
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In this paper, the DSC technique has been used to study
the interaction of gemcitabine and three of its prodrugs, with
dimyristoylphosphatidylcholine (DMPC) and distearoylphos-
phatidylcholine (DSPC), as well as to monitor uptake
experiments as a function of the time, to gain information
on the transfer of such compounds through an aqueous
medium. The procedure previously described to study the
interaction of similar compounds with DMPC multilamellar
vesicles19,20 has been here followed.
The calorimetric investigation of the interaction between
bioactive compounds and membranes was carried out by
following a “classical” method (by dissolving the bioactive
compounds and the lipids in organic solvent before multi-
lamellar vesicle preparation) that can only be considered as
a way to detect the maximum interaction between a foreign
molecule and the lipid bilayer. The data obtained by the
“classical” method and those obtained by the transfer
experiments are compared each other. The comparison gives
information on the ability of a compound to permeate the
aqueous layer surrounding the lipid membrane, reach the
outer lipid layer, and pass through the internal layers,
penetrating into a cell-like model.19-23 In this way it is
possible to have knowledge in the understanding of the
penetration routes of such antitumor agents by modulating
their lipophilicity. The data are compared with those obtained
by using fatty acids (valeric acid, C5; lauric acid, C12, and
stearic acid, C18) to better define the influence of the
hydrophobic chain on the interaction of the 4-(N)-acyl-
gemcitabine derivatives with model membranes.
Experimental Section
Materials. Gemcitabine was synthesized in our laboratory
following the procedure reported in the literature.24 The
synthesis of 4-(N)-acyl-gemcitabine derivatives as well their
characterization was reported in a previous paper by some
of us.13
1,2-Dimyristoyl-sn-glycero-3-phosphatidylcholine was sup-
plied by Genzyme Pharmaceuticals (Liestal, Switzerland).
1,2-Distearoyl-sn-glycero-3-phosphatidylcholine, valeric acid,
lauric acid, and stearic acid were supplied by Fluka Sigma
Aldrich (Switzerland).
Lipids were chromatographically pure as assessed by two-
dimensional thin-layer chromatography. Lipid concentrations
were determined by phosphorus analysis.25 100 mM phos-
phate buffer solution, adjusted to pH 7.4, was employed. All
other reagents and solvents used were of analytical grade
from Carlo Erba Reagenti (Milan, Italy).
MLV Preparation. To obtain DMPC or DSPC multila-
mellar vesicles, in the presence and absence of gemcitabine
and 4-(N)-acyl-gemcitabine derivatives and pure fatty acids,
chloroform stock solutions of compounds were prepared.
Aliquots of the DMPC or DSPC solution were delivered in
glass tubes in order to have the same amount (0.010 32
mmol) of lipid, and then aliquots of gemcitabine or gem-
citabine prodrugs or fatty acid solution were added in order
to have 0.00 and 0.12 molar fractions of compound with
respect to the lipid. Solvents were removed under nitrogen,
and the resulting film was freeze-dried to remove the residual
solvents. Phosphate buffer solution (168 íL; 100 mM pH
7.4) was added to the films, to obtain liposomes. The samples
were heated to 37 °C (DMPC) or 65 °C (DSPC) (tempera-
tures above the gel-liquid crystalline phase transition
happening at 24.8 °C for DMPC and 55.1 °C for DSPC)
and vortexed three times for 1 min. The samples were left
for 1 h at 37 or 65 °C to homogenize the liposomes and to
allow the redistribution of the compounds between lipid and
aqueous phases; the liposomes being in a disordered phase,
the compounds’ partition is favored. Aliquots of 120 íL of
lipid suspension (0.007 375 mmol of lipids) were then
transferred to a 160 íL DSC aluminum pan, hermetically
sealed, and submitted to DSC analysis. Phospholipid phos-
phorus content was assessed in each liposome preparation
by phosphate assay after destruction with perchloric acid.25
Size distribution of liposomes was monitored by photon
correlation spectroscopy using a Coulter model N4SD
submicron particle analyzer (Coulter Electronics, Florida,
USA).
LUV Preparation. To obtain LUV, MLV were repeti-
tively (19 times) passed under moderate pressure at a
(16) Marsh, D. Physical characterisation of liposomes for understanding
structure-function relationships in biological membranes. In
Nonmedical Applications of Liposomes; Barenholz, Y., Lasic, D.
D., Eds.; CRC Press: Boca Raton, FL, 1996; Vol. II, pp 1-16.
(17) Jain, M. K. In Introduction to Biological Membranes; Jain, M.
K., Ed.; Wiley: New York, 1988; pp 122-165.
(18) Huang, C.; Li, S. Calorimetric and molecular mechanics studies
of the thermotropic phase behavior of membrane phospholipids.
Biochim. Biophys. Acta 1999, 1422, 273-307 (and references
cited therein).
(19) Raudino, A.; Castelli, F. Modeling specific heat transient anoma-
lies during permeation of liposomes by water-soluble substances.
J. Colloid Interface Sci. 1998, 200, 52-58.
(20) Castelli, F.; Uccella, N.; Saija, A.; Trombetta, D. Differences
between Coumaric and Cinnamic Acids in membrane permeation
as evidenced by time-dependent calorimetry. J. Agric. Food Chem.
1999, 47, 991-995.
(21) Raudino, A.; Castelli, F. Transport through monolayers and
bilayers at fluid-fluid interfaces. In Encyclopedia of Colloid and
Interface Science; Hubbard, A., Ed.; Marcel Dekker: New York,
2002; pp 5441-5455.
(22) Castelli, F.; Pitarresi, G.; Giammona, G. Influence of different
parameters on drug release from hydrogel systems to biomembrane
model. Evaluation by differential scanning calorimetry technique.
Biomaterials 2000, 21, 821-833.
(23) Castelli, F.; Giunchedi, P.; La Camera, O.; Conte, U. A calori-
metric study on Diflunisal release from poly(lactide-co-glycolide)
microspheres by monitoring the drug effect on Dipalmitoylphos-
phatidylcholine liposomes: Temperature and drug loading influ-
ence. Drug DeliVery 2000, 7, 45-53.
(24) Hertel, L. W.; Kroin, J. S.; Misner, J. W.; Tustin, J. M. Synthesis
of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2-difluoro-D-
ribofuranosyl nucleosides. J. Org. Chem. 1987, 53, 2406-2409.
(25) Rouser, G.; Fleischer, J.; Yamamoto, A. Two dimensional thin
layer chromatographic separation of polar lipids and determination
of phospholipids by phosphorus analysis of spots. Lipids 1970,
5, 494-496.
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temperature at least 5 °C above the Tm through polycarbonate
membranes (pore diameter 100 nm) in an extruder system
(LiposoFast Basic, Avestin Inc.).26,27 The membrane pores
are almost cylindrical, and vesicles (unilamellar or multila-
mellar) that are larger than the mean pore diameter are
reduced in size and lamellarity during the passage through
the pores, resulting in final vesicle size that corresponds to
the mean size of the pores.28,29
Differential Scanning Calorimetry. DSC was performed
by using a Mettler TA Stare system equipped with a DSC
822e calorimetric cell and Mettler STARe V 6.10 SW
software. The scan heating rate employed was 2 °C/min in
the temperature range 5-37 °C for DMPC and 25-65 °C
for DSPC. The sensitivity was automatically chosen as the
maximum possible by the calorimetric system, and the
reference pan was filled with phosphate buffer solution. The
calorimetric system was calibrated, in temperature and
enthalpy changes, by using indium, stearic acid, and cyclo-
hexane by following the procedure of the Mettler TA STARe
software.
To check the reproducibility of the results, the calorimetric
scan was repeated at least four times; aliquots of all samples
were then extracted from calorimetric aluminum pans and
used to determine, by the phosphorus assay,25 the exact
amount of phospholipids present in each sample.
Permeation Experiments. A fixed amount of powdered
or liquid (valeric acid) compound (aimed at obtaining a 0.12
molar fraction with respect to the phospholipid) was placed
in the bottom of the 160 íL DSC aluminum crucible, and
then 120 íL of DMPC or DSPC MLV or DMPC LUV
(0.007 375 mmol of phospholipids dispersed in phosphate
buffer) was added. The samples, hermetically sealed in the
pans, were gently shaken for 10 s and then submitted to the
following calorimetric cycles: (1) a heating scan, at the rate
of 2 °C/min, between 5 and 37 °C (DMPC) or between 25
and 65 °C (DSPC), to detect the interaction between the
compounds and the model membrane during the first heating
of the sample to a temperature higher than the Tm; (2) an
isothermal period (1 h) at 37 or 65 °C to allow the
compounds to be hydrated, to dissolve in the aqueous
medium, and eventually to interact and permeate the lipid
layers, which at the chosen temperatures (above the lipid
transition temperature) are in a disordered state; (3) a cooling
scan between 37 and 5 °C (DMPC) or between 65 and 25
°C (DSPC), at the rate of 4 °C/min, to bring the lipid layers
back to an ordered state before restarting the heating program
(step 1).
This procedure was run at least six times, and after a longer
incubation time (72 h) to follow eventual variations of the
transition temperature of the DMPC or DSPC calorimetric
peak due to the time dependent compound-model membrane
interaction.
Results
Gemcitabine and Gemcitabine Prodrug Interaction
with DMPC MLV Prepared in Organic Phase. Pure
DMPC liposomes show a sharp main peak at 24.8 °C (Tm),
associated with the gel to liquid crystalline phase transition,
and a pretransition peak at about 16.8 °C which reflects a
change in tilt of the hydrocarbon chains.
In Figure 2 the calorimetric curves of unloaded or loaded
liposomes with gemcitabine, 4-(N)-valeroyl-gemcitabine,
4-(N)-lauroyl-gemcitabine, and 4-(N)-stearoyl-gemcitabine at
the molar fraction X ) 0.12 are reported. Gemcitabine causes
no significant change in the peak shape and transition
(26) MacDonald, R. C.; MacDonald, R. I.; Menco, B. P. M.; Takeshita,
K.; Subbarao, N. K.; Hu, L. Small-volume extrusion apparatus
for preparation of large, unilamellar vesicles. Biochim. Biophys.
Acta 1991, 1061, 297-303.
(27) Hope, M. J.; Bally, M. B.; Webb, G.; Cullis, P. R. Production of
large unilamellar vesicles by a rapid extrusion procedure. Char-
acterization of size distribution, trapped volume and ability to
maintain a membrane potential. Biochim. Biophys. Acta 1985, 812,
55-65.
(28) Mayer, L. D.; Hope, M. J.; Cullis, P. R. Vesicles of variable sizes
produced by a rapid extrusion procedure. Biochim. Biophys. Acta
1986, 858, 161-168.
(29) Hope, M. J.; Nayar, R.; Mayer, L. D.; Cullis, P. R. Reduction of
Liposome Size and Preparation of Unilamellar Vesicle by Extru-
sion Techniques. In Liposome Technology; Gregoriadis, G., Ed.;
CRC Press, Inc.; Boca Raton, FL, 1993; Vol. I, pp 123-140.
Figure 2. Calorimetric curves of DMPC MLV prepared in the
absence and in the presence of gemcitabine (Gem) and its
prodrugs 4-(N)-valeroyl-gemcitabine (Gem-C5), 4-(N)-lauroyl-
gemcitabine (Gem-C12), and 4-(N)-stearoyl-gemcitabine (Gem-
C18) at 0.12 molar fraction with respect to phospholipids.
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temperature. All the prodrugs shift the calorimetric curve
toward lower temperatures with respect to the pure DMPC.
The 4-(N)-stearoyl-gemcitabine exerts the greatest effect on
the Tm accompanied by a broadening of the curve with the
concomitant disappearance of the pretransition peak. Such
effects, in the presence of 0.12 molar fraction of compounds
in the aqueous dispersion, will be considered as a reference
for the most complete interaction between compounds and
lipids.
Gemcitabine and Gemcitabine Prodrug Interaction
with DMPC MLV. Permeation Experiments. Uptake
experiments were performed to study the ability of gemcit-
abine, its 4-(N)-acyl-gemcitabine derivatives, and the pure
fatty acids to go through the aqueous phase surrounding the
compounds, to be absorbed on the external lipid bilayer of
multilamellar vesicles, and successively to be transferred into
the deeper lipid bilayers, with the aim of obtaining informa-
tion about the influence of the fatty acid moiety on such a
process. The calorimetric curves obtained by leaving a fixed
amount (X ) 0.12) of gemcitabine (or its prodrugs) in contact
with DMPC multilamellar vesicles, following the procedure
reported in the Permeation Experiments section, are reported
in Figure 3A-D and compared with the curve of DMPC
MLV prepared in the presence of each compound at a 0.12
molar fraction (curves r), as reported in the MLV Preparation
section. If a full penetration of the lipid layers occurs, a
calorimetric effect similar to curve r should be obtained.
It appears evident that gemcitabine (Figure 3A) leaves the
transition temperature nearly unchanged. A different behavior
is observable among the three prodrugs. In fact only Gem-
C5 (Figure 3B) exerts an increasing effect on the lipid phase
transition, as the contact time increases, causing a fast shift
of the temperature toward the same value observed in curve
r and a concomitant disappearance of the pretransition peak.
Lauroyl (Figure 3C) and stearoyl prodrugs (Figure 3D) do
not exert such a rapid and complete interaction. In fact, the
calorimetric peaks remain nearly unchanged in shape and
temperature, and far away from the curves r. The data appear
better comparable by reporting (Figure 4) the effects of the
compounds, at the fixed molar fractions present in the
aqueous lipid dispersion, on the lipid transition temperature
shifts as (¢T  103)/T0m (¢T ) T0m - Tm, where T0m is the
transition temperature of pure DMPC and Tm is the transition
temperature of each compound/DMPC aqueous dispersion),
as a function of the contact time. It is evident that Gem-C5
Figure 3. Calorimetric curves of DMPC MLV left in contact,
at increasing incubation time and at 37 °C, with 0.12 molar
fraction of (A) gemcitabine, (B) 4-(N)-valeroyl-gemcitabine, (C)
4-(N)-lauroyl-gemcitabine, and (D) 4-(N)-stearoyl-gemcitabine.
Curve r is referred to DMPC MLV prepared in the presence
of compounds (0.12 molar fraction with respect to phospho-
lipids) and represents the maximum obtainable shift by MLV/
compound interaction.
Figure 4. Transition temperature variations of DMPC MLV
left in the presence of compounds at 0.12 molar fraction with
respect to phospholipids. ¢T ) T0m - Tm, where T0m is the
transition temperature of pure DMPC vesicles and Tm is the
transition temperature of DMPC vesicles left in the presence
of compound at increasing incubation time. The r values
represent the effect exerted by 0.12 molar fraction of each
compound on MLV, obtained starting from organic solvent
solutions of phospholipids and compounds, to be considered
as the maximum interaction between compounds and MLV.
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quickly reaches the maximum effect similar to that of the
“organic” preparation (value r obtained from the curve r
reported in Figure 3). Gem-C12 after a long time of contact
with the MLV tends to increase the Tm shift. Gemcitabine
and Gem-C18 are unable to affect the transition temperature,
which is very far from that found in the case of the maximum
interaction (the r value).
Gemcitabine and Gemcitabine Prodrug Interaction
with DMPC LUV. Permeation Experiments. The calori-
metric curves of DMPC LUV left in contact with gemcitabine
or its prodrugs at increasing incubation time (curves not
reported) show that gemcitabine does not affect the LUV
transition, whereas all the prodrugs cause the shift of the
peak toward lower temperature. Such a shift is more
pronounced when Gem-C18 is used, which causes in addition
the peak broadening. The results are compared in Figure 5,
where the transition temperature variation is reported, as ¢T/
T0m, as a function of the incubation time: Gem-C5 shows a
quick kinetics of interaction reaching the value r (maximum
interaction); Gem-C12 and Gem-C18 show a tendency to
slowly reach the values r.
Fatty Acid Interaction with DMPC MLV by Organic
Phase and Permeation Experiments. Calorimetric mea-
surements of pure DMPC MLV prepared either in the
absence or in the presence of a 0.12 molar fraction of the
same fatty acid used in the prodrug formulation were carried
out. They demonstrate that the interaction between 4-(N)-
acyl-gemcitabine derivatives and the lipid vesicles must be
assigned to the entire prodrug molecule and not solely to
the apolar fatty acid tail. Valeric acid causes no changes in
the DMPC calorimetric curve, while lauric and stearic acids
produce a broadening and a large shift of the main peak
toward higher temperature and the disappearance of the
pretransition peak (curves not reported).
The comparison of the calorimetric curves of DMPC MLV
left in contact with fatty acids (0.12 molar fraction) at
increasing incubation times with that of pure DMPC MLV
and with those prepared in the presence of a 0.12 molar
fraction of each fatty acid reveals that lauric acid interacts
by broadening the curve (with a phase separation during the
first incubation periods) and by shifting the peak toward
higher temperatures. Stearic acid, during the first 8 h of
incubation, does not modify the DMPC MLV curves,
whereas after 72 h it causes peak broadening and a phase
separation. Valeric acid does not modify the DMPC calo-
rimetric curve (data not reported). The results are shown in
Figure 6, where the temperature variations, ¢T/T0m, are
reported as a function of the incubation time. Valeric acid
does not cause any temperature variation. Temperature
variation caused by lauric acid regularly increases with the
incubation time. When stearic acid is considered, the
temperature variation is constant up to 8 h; thereafter it
sharply increases around 72 h.
Gemcitabine and Gemcitabine Prodrug Interaction
with DSPC MLV Prepared in the Organic Phase. The
calorimetric curve of DSPC MLV presents a main peak, at
55.1 °C (Tm), associated with the transition from a gel to a
liquid crystalline phase, a pretransition peak, at about 51.8
Figure 5. Transition temperature variations of DMPC LUV
left in the presence of compounds at 0.12 molar fraction with
respect to the phospholipids. ¢T ) T0m - Tm, where T0m is
the transition temperature of pure DMPC vesicles and Tm is
the transition temperature of DMPC vesicles left in the
presence of compound at increasing incubation time. The r
values represent the effect exerted by 0.12 molar fraction of
each compound on vesicles, obtained starting from organic
solvent solutions of phospholipids and compounds, to be
considered as the maximum interaction between compounds
and LUV.
Figure 6. Transition temperature variations of DMPC MLV
left in the presence of compounds at 0.12 molar fraction with
respect to the phospholipids. ¢T ) T0m - Tm, where T0m is
the transition temperature of pure DMPC vesicles and Tm is
the transition temperature of DMPC vesicles left in the
presence of compound at increasing incubation time. The r
values represent the effect exerted by 0.12 molar fraction of
each compound on MLV, obtained starting from organic
solvent solutions of phospholipids and compounds, to be
considered as the maximum interaction between compounds
and MLV.
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°C, related to a change in tilt of the hydrocarbon chains and
a small shoulder next to the main peak. The curves of DSPC
MLV prepared in the presence of 0.12 molar fractions of
gemcitabine, Gem-C5, Gem-C12, and Gem-C18 show that
these compounds produce different effects on the DSPC
MLV phase transition (curves not reported). Gemcitabine
shifts the peak toward higher temperatures without changing
its shape; the valeroyl derivative negligibly affects the DSPC
calorimetric peak, whereas the stearoyl derivative and, even
more, the lauroyl derivative cause a large shift toward lower
temperature accompanied by a peak broadening. Stearoyl and
lauroyl derivatives suppress the pretransition peak and the
small shoulder characteristic of the DSPC curve.
Such an interaction (in the presence of 0.12 molar fraction
of the compounds in the aqueous liposomal dispersion) is
considered as the highest possible between compounds and
lipids in the liposomes.
Gemcitabine and Gemcitabine Prodrug Interaction
with DSPC MLV. Permeation Experiments. The calori-
metric curves obtained by permeation experiments using 0.12
molar fraction of gemcitabine, or its prodrugs, in the presence
of DSPC multilamellar vesicles are compared with those of
pure DSPC MLV and DSPC MLV prepared in the presence
of 0.12 molar fraction of each compound (data not shown).
The first result is that gemcitabine leaves nearly unchanged
the phase transition temperature of pure DSPC; also the
pretransition peak and the shape of the curves remain
unchanged. Prodrugs show a different behavior. In fact, Gem-
C5 increasingly shifts the temperature toward the same value
observed in curve r (homogeneous dispersion of the prodrug
in the lipid matrix), with a concomitant disappearance of
the pretransition and a modification of the DSPC peak.
Instead Gem-C12 causes only a small shift toward lower
temperatures leaving the peaks nearly unchanged in shape
and far from the curve r. Gem-C18 modifies both the
temperature and the shape of the calorimetric peak. The data
are compared each other in Figure 7, which shows the effects
of the compounds, at fixed molar fraction, on the lipid
transition temperature shifts, ¢T/T0m, as a function of the
contact time. Gemcitabine does not perturb the DSPC
vesicles, while Gem-C5 quickly reaches the maximum effect
(value r). Gem-C12 and Gem-C18 slowly increase the Tm
shift without reaching the maximum of the interaction.
Fatty Acid Interaction with DSPC MLV by Organic
Phase and Permeation Experiments. The calorimetric
curves obtained by dissolving a 0.12 molar fraction of the
same fatty acids present in the gemcitabine prodrug formula-
tion in DSPC multilamellar vesicles (during their preparation
in the organic phase) reveal that lauric acid and stearic acid
interact with DSPC MLV (curves not reported). Both the
fatty acids produce a broadening of the main peak, but lauric
acid shifts the peak toward lower temperature whereas stearic
acid shifts the peak toward higher temperature with a
concomitant phase separation. Valeric acid is unable to
modify the DSPC MLV calorimetric curves.
The calorimetric data (not reported) of the experiments
carried out by leaving DSPC MLV in contact with the
compounds (0.12 molar fraction) show that valeric acid
Figure 7. Transition temperature variations of DSPC MLV
left in the presence of compounds at 0.12 molar fraction with
respect to the phospholipids. ¢T ) T0m - Tm, where T0m is
the transition temperature of pure DSPC vesicles and Tm is
the transition temperature of DSPC vesicles left in the
presence of compound at increasing incubation time. The r
values represent the effect exerted by 0.12 molar fraction of
each compound on MLV, obtained starting from organic
solvent solutions of phospholipids and compounds, to be
considered as the maximum interaction between the com-
pound and MLV.
Figure 8. Transition temperature variations of DSPC MLV
left in the presence of compounds at 0.12 molar fraction with
respect to the phospholipids. ¢T ) T0m - Tm, where T0m is
the transition temperature of pure DSPC vesicles and Tm is
the transition temperature of DSPC vesicles left in the
presence of compound at increasing incubation time. The r
values represent the effect exerted by 0.12 molar fraction of
each compound on MLV, obtained starting from organic
solvent solutions of phospholipids and compounds, to be
considered as the maximum interaction between the com-
pound and MLV.
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produces no detectable effects whereas lauric acid shifts the
main peak toward lower temperature, changing the curve
shape, which becomes very similar to the curve of MLV
prepared in the presence of a 0.12 molar fraction of fatty
acids. More complex is the interaction of the stearic acid:
the main peak broadens, leading to a phase separation which
increases with the time. The results are summarized in Figure
8, where we report ¢T/T0m as a function of contact time.
Valeric acid causes a very small effect on transition tem-
perature. Lauric and stearic acids cause a decrease and an
increase of the transition temperature, respectively; in any
case the equilibrium value r is never reached.
Discussion
The obtained data suggest that gemcitabine by itself is not
able to perturb the employed biomembrane models (DMPC
MLV and LUV and DSPC MLV). Instead, gemcitabine
bound to fatty acids, to form 4-(N)-acyl derivatives prodrugs,
shows a substantial and greater interaction with the consid-
ered biomembrane models. The entity of the interaction
depends on the acyl chain length of both phospholipids and
prodrugs. The DSC data demonstrate that generally all
prodrugs exert a destabilizing effect on biomembranes,
changing their thermotropic behavior. In particular, the
prodrugs decrease the transition temperature with respect to
that of pure phospholipids.
Considering the behavior of MLV prepared in the presence
of prodrug and comparing the results obtained with DMPC
MLV with those obtained with DSPC MLV, it is noted that
Gem-C5 shows a similar effect on the two model membranes.
The two remaining prodrugs show a different behavior:
Gem-C12 exerts a bigger destabilizing effect on DSPC MLV,
whereas Gem-C18 exerts a stronger destabilizing effect
toward DMPC MLV. These results are attributable to the
different length of the hydrocarbon chains present in the two
membrane systems (DMPC and DSPC) with respect to the
prodrug’s hydrocarbon chain; in particular the bigger the
chain length difference between phospholipid and prodrug,
the greater the prodrug destabilizing effect. Gem-C12,
possessing a hydrophobic chain similar to that of DMPC,
does not destabilize the lipid bilayer as Gem-C18 does. On
the other hand, Gem-C18 exerts a smaller destabilizing effect
on DSPC bilayer, its hydrophobic portion being nearly equal
to that of DSPC, whereas Gem-C12, whose hydrophobic
chain is shorter than that of DSPC, perturbs the phospholipid
bilayer.
The comparison of the results obtained by employing
prodrugs with those obtained by using the fatty acids shows
that the destabilizing effect exerted by the prodrug is
assignable to the joint gemcitabine-fatty acid and not only
to the fatty acid because they exert opposite effects on MLV.
In particular, according to the literature data,30 fatty acids
alone increase the Tm of the lipid bilayer (the only exception
being represented by the lauric acid) whereas prodrugs
decrease it. This evidence leads us to hypothesize that the
fatty acid contribution in prodrug/MLV interaction favors
the insertion of gemcitabine inside the lipid bilayer.
This hypothesis is supported by the results obtained for
permeation kinetics of prodrugs and fatty acids. In such
conditions prodrugs reach the inner lipid bilayer of multi-
lamellar liposomes. The rate of such interaction depends on
the hydrophobic tail length of the prodrug: Gem-C5, the
less lipophilic among the three prodrugs, despite showing
the smallest interaction in prodrug/phospholipid MLV,
possesses the fastest interaction rate; Gem-C12, possessing
an intermediate lipophilicity, shows both an intermediate
interaction in prodrug/phospholipid MLV and rate of transfer
in kinetic experiments; Gem-C18, the most lipophilic pro-
drug, shows the biggest interaction with the lipid membrane
and the slowest transfer rate. This is because its motion
through the aqueous phase is hindered by its lipophilic
character.
The interaction of gemcitabine prodrugs with LUV differs
from that with MLV, being faster and more complete. Given
that LUV are constituted by a single bilayer, they expose a
surface much larger than that of MLV for the contact with
the prodrugs. It could be the reason of the faster and more
complete LUV/compound interaction. These experiments
strengthen the hypothesis that the limiting step in the
interaction prodrug/phospholipid bilayer is the prodrug
dissolution in the aqueous medium.
The calorimetric data highlight the prodrugs’ ability to
interact with biomembranes. Prodrugs (apart from Gem-C5)
are subjected to a slow uptake by MLV; the rate of their
passage through the aqueous medium to reach the lipid
vesicles is hindered by their low solubility due to their
lipophilic nature.
The present study was aimed at determining the differences
in the mechanism of dissolution, transport through the
aqueous phase, and absorption by lipidic systems mimicking
biomembranes of gemcitabine and three of its 4-(N)-acyl
derivatives. It was evidenced, as partially reported in a
previous study of some of us,13 that the efficiency of a
liposomal system is related to the length of the prodrug’s
acyl chain, which has to match the phospholipid acyl chain
allowing or retarding the migration through the lipidic release
device.
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